Vistagen Q2 net loss $17.5M; PALISADE-2 restart after interim analysis

Vistagen Therapeutics, Inc.

Net loss $17.5M vs $13.2M YoY; R&D spend $12.9M (+$2.9M) on PH94B/PH10 trials.
Cash and equivalents $35.3M; shares outstanding 206.8M as of Nov 9, 2022.
Independent interim analysis recommends continuing PALISADE-2 Phase 3 PH94B trial; restart preparations underway.
Preliminary PALISADE Open Label data (n≈400) shows LSAS functional improvement; full assessment Q1 2023.
IND submitted to FDA for PH10 Phase 1 study in healthy volunteers to enable Phase 2B in major depressive disorder.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vistagen Therapeutics, Inc. reported financial results for its fiscal year 2023 second quarter ended September 30, 2022.

Period: its fiscal year 2023 second quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 second quarter ended September 30, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001851734-22-000663

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.